A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with hepatic impairment.
Trial Details
- NCT ID
- NCT07853040
- Phase
- PHASE1
- Sponsor
- Incyte Corporation
- Status
- RECRUITING
- Cancer Type
- Liver Cancer
- Interventions
- Locations (sample)
- Chandler, Arizona, United States|33.30616,-111.84125
- Orlando, Florida, United States|28.53834,-81.37924
- San Antonio, Texas, United States|29.42412,-98.49363
Key Eligibility Criteria
- Ability to comprehend and willingness to sign a written ICF for the study.
- Age 18 to 80 years (inclusive) at the time of signing the ICF.
- Moderate or severe hepatic impairment based on Child-Pugh score.
- Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 1…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →